154566-05-9
154566-05-9
Chemical Structure
SB-201076
- CAS No.: 154566-05-9
- Formula:C18H24Cl2O6
- Molecular Weight:407.29
InChIKey: NPZOIISFQXTCQN-KBXCAEBGSA-N
SMILES: OC(C[C@](C(O)=O)(O)C[C@@H](O)CCCCCCC1=C(C=C(C=C1)Cl)Cl)=O
Biological Activity: SB-201076 is an orally active inhibitor of ATP citrate lyase (Ki=1 μM). SB-201076 is applicable to research related to hyperlipidemia and cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB-201076 | SB-201076 is an orally active inhibitor of ATP citrate lyase (Ki=1 μM). SB-201076 is applicable to research related to hyperlipidemia and cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. The Biochemical journal. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9. [Content Brief]
- [2]. Zu XY, et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent patents on anti-cancer drug discovery. 2012 May 01;7(2):154-67. [Content Brief]
